Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280865 · ClinicalTrials.gov registry record · Phase 2
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT00280865 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 500 participants.
The verdict
NCT00280865, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 2-week enrollment period, 4 week placebo single blind run in period followed by a 12-week double blind treatment period and a 3-week follow-up period
Interventions
- DRUG Pioglitazone
- DRUG Tesaglitazar
- BEHAVIORAL Dietary and Lifestyle Modification Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2002-04 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00280865
The ClinicalTrials.gov registry entry for NCT00280865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pioglitazone is the first listed.
NCT00280865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00280865 about?
NCT00280865 is a clinical study titled "GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes". This is a 12-week randomized, double-blind, multi-center, active-controlled (open-label pioglitazone) and placebo-controlled study of tesaglitazar (0.1, 0.5, 1, 2, and 3 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The s...
What is the current status of trial NCT00280865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2002-04. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00280865?
The interventions under investigation include: Pioglitazone (DRUG), Tesaglitazar (DRUG), Dietary and Lifestyle Modification Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00280865?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.